Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution

Rallybio Corp

• Avenzo Therapeutics merger under May 31, 2026 agreement expected to close after market close Nov 20, 2026; Nasdaq approved listing of common stock for the deal.
• Special cash distribution of $13.90/share to holders of record Nov 5, 2026; deposit with transfer agent Nov 19, payments expected to begin Nov 30, 2026.
• Nasdaq due-bill period runs from Nov 5 record date through close on Nov 20; buyers in that period receive the cash distribution, while sellers do not.
• Reverse stock split expected effective 4:01 p.m. ET on Nov 20, 2026; timing and amount of the cash distribution are unaffected.
• Contingent value rights expected distributed Nov 23, 2026 to common holders, pre-funded warrants, RSUs and In the Money Parent Options as of Nov 5.